Immunomodulatory effect of macrolides: At what cost?

Maria Kipourou; Katerina Manika; Apostolos Papavasileiou; Georgia Pitsiou; Martha Lada; Evangelos Ntinapogias; Ioannis Kioumis

doi:10.1016/j.rmcr.2016.01.004

Immunomodulatory effect of macrolides: At what cost?

Respir Med Case Rep. 2016 Jan 15:17:44-6. doi: 10.1016/j.rmcr.2016.01.004. eCollection 2016.

Authors

Maria Kipourou¹, Katerina Manika², Apostolos Papavasileiou³, Georgia Pitsiou⁴, Martha Lada², Evangelos Ntinapogias⁵, Ioannis Kioumis²

Affiliations

¹ Respiratory Infections Unit, Pulmonary Department, Aristotle University of Thessaloniki, G. Papanikolaou Hospital, Thessaloniki, Greece; Pulmonary Department, 424 General Military Hospital, Thessaloniki, Greece.
² Respiratory Infections Unit, Pulmonary Department, Aristotle University of Thessaloniki, G. Papanikolaou Hospital, Thessaloniki, Greece.
³ Tuberculosis Department, 'Sotiria' Chest Diseases Hospital, Athens, Greece.
⁴ Respiratory Failure Unit, Aristotle University of Thessaloniki, Thessaloniki, Greece.
⁵ Pulmonary Department, 424 General Military Hospital, Thessaloniki, Greece.

Abstract

We present the case of a 60-year old female patient, with a 10 year history of non-CF bronchiectasis and use of macrolides as maintenance immunomodulatory treatment, who was diagnosed with macrolide-resistant Mycobacterium avium complex lung disease. Macrolides' immunomodulatory effect is appealing for non- CF bronchiectasis patients, hiding a high risk for resistance emergence.

Keywords: Bronchiectasis; Macrolides; Non-tuberculous mycobacteria.

Publication types

Case Reports